Loading
Discovered how lenalidomide works, launching the field of molecular-glue degraders, and defined clonal haematopoiesis before leading Dana-Farber.
Benjamin L. Ebert is President and Chief Executive Officer of Dana-Farber Brigham Cancer Center and a haematologist-scientist working on myeloid malignancies and multiple myeloma. He is known for discovering how lenalidomide works, showing that it induces degradation of IKZF1, IKZF3 and CK1 alpha through cereblon, which launched the field of molecular glue degraders. He also defined clonal haematopoiesis of indeterminate potential. His selected papers cover clonal haematopoiesis and blood cancer risk inferred from blood DNA sequence, and lenalidomide's selective degradation of IKZF1 and IKZF3 in myeloma cells. He has led Dana-Farber since 2024 and received the Sjöberg Prize the same year.
| Title | Journal | Year |
|---|---|---|
| Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence | New England Journal of Medicine | 2014 |
| Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells | Science | 2014 |
Shares American Society of Hematology, Dana-Farber Brigham Cancer Center, Lenalidomide, Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Dana-Farber Brigham Cancer Center, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Howard Hughes Medical Institute, Dana-Farber Brigham Cancer Center.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares American Society of Hematology, Acute myeloid leukaemia.